From April 8th.
Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $220.00 price target on Sage Therapeutics (NASDAQ: SAGE) after hosting a key opinion leader (KOL) call with Dr. Lee Altman, who is a practicing psychiatrist and currently treats ~1000 patients with schizophrenia and/or
depressive disorders. Key takeaways:
1) the KOL likes SAGE-217's rapid onset of action
2) is especially enthusiastic about the remission rate, given the data seen so far on the product
The analyst stated "While Dr. Altman said he is eager to see longer-term data, he believes SAGE-217 could play a part in the treatment of depressive disorders if the product successfully navigates through the clinical development and regulatory processes".